Wall Street Breakfast Podcast: Allurion Soars On Balloon And GLP-1 Study Plans
Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...
Business Wire3d
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment
These statements relate to, among other things, the anticipated benefits and impact of the AI-driven peptide discovery pipeline, the potential for computationally designed GLP-1 analogs to improve ...
Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.
BioSpace1d
Novo Rebounds as Next-Gen Obesity Drug Elicits up to 22% Weight Loss
The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...
Q&A: Aging and Alzheimer's disease—investigating drug effects
The geroscience hypothesis focuses on extending the healthy lifespan by targeting aging mechanisms. Recent advances in ...
Medical Xpress5d
Q&A: Aging and Alzheimer's disease—investigating drug effects
Study III investigated the genetic effects of antidiabetic drugs on AD risk, revealing that sulfonylureas and GLP-1 analogs significantly reduced the risk of AD, by approximately 60% and 70% ...